Current Research: Pediatric Hematology-Oncology

ALTE03N1 --Study of Late-Occurring Complications in Childhood Cancer Survivors

A patient's genes may affect the risk of developing complications, such as congestive heart failure, heart attack, stroke, and second cancer, years after undergoing cancer treatment. Genetic studies may help doctors identify survivors of childhood cancer who are more likely to develop late complications.

This clinical trial is studying cancer survivors to identify those who are at increased risk of developing late-occurring complications after undergoing treatment for childhood cancer.

Eligibility

Cases will consist of patients experiencing a key adverse event, who meet the following criteria:

1. Diagnosis of primary cancer at age 21 or younger, irrespective of current age.
2. Development of one of the following key adverse events
   • Congestive heart failure (CHF)
   • Myocardial infarction (MI)
   • Ischemic stroke (IS)
   • Avascular necrosis (AVN)
   • Subsequent malignant neoplasm (SMN)
3. Inactive follow up by a COG institution. (Active follow up will be defined as date of last visit or contact by a COG institution within the past 24 months.)

Trial Sponsor

• Children’s Oncology Group (COG); National Cancer Institute (NCI)

Project Begin Date

• Nov 2007

Tentative Project End Date

• Ongoing

Back to Pediatric Hematology-Oncology Research

Revised March 30, 2009.   Please send comments, suggestions or questions about this page to Goldei Posey, gposey@mcg.edu .